<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12284">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947022</url>
  </required_header>
  <id_info>
    <org_study_id>16-1080</org_study_id>
    <nct_id>NCT02947022</nct_id>
  </id_info>
  <brief_title>Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease</brief_title>
  <official_title>Investigator Initiated Investigational New Drug Application to Study the Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hameln Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: There are two goals we have for this prospective single arm study; to see an
      increase in the amount of gadolinium in 24 hour urine collection following each infusion
      treatment with Calcium and Zinc DTPA, and to see a reduction or elimination of gadolinium
      deposition disease (GDD) symptoms.

      Participants: Twenty (20) patients who are suffering from gadolinium deposition disease
      (GDD)

      Procedures: Over a series of three (3) treatment time-points patients will be treated with
      IV Ca-DTPA on day one, and Zn-DTPA on day two.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Month 1 in Gd level from 24-hour urine samples following Calcium DTPA administration.</measure>
    <time_frame>Baseline, Month 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline to Month 1 in Gd level from 24-hour urine samples following Zinc DTPA administration.</measure>
    <time_frame>Baseline, Month 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Month 2 in Gd level from 24-hour urine samples following Calcium DTPA administration.</measure>
    <time_frame>Baseline, Month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Month 2 in Gd level from 24-hour urine samples following Zinc DTPA administration.</measure>
    <time_frame>Baseline, Month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Month 3 in Gd level from 24-hour urine samples following Calcium DTPA administration.</measure>
    <time_frame>Baseline, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Month 3 in Gd level from 24-hour urine samples following Zinc DTPA administration.</measure>
    <time_frame>Baseline, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 1 in the Pain Score</measure>
    <time_frame>Baseline, Month 1 (Day 7)</time_frame>
    <description>Patient self-reported pain scores assessed using a Visual Analog Scale (VAS) ranging from 0 to 10 where 0 indicates &quot;no pain&quot;, 4 through 6 reflect &quot;moderate pain&quot;, and 10 reflects &quot;worst possible pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 2 in the Pain Score</measure>
    <time_frame>Baseline, Month 2 (Day 7)</time_frame>
    <description>Patient self-reported pain scores assessed using a VAS ranging from 0 to 10 where 0 indicates &quot;no pain&quot;, 4 through 6 reflect &quot;moderate pain&quot;, and 10 reflects &quot;worst possible pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 3 in the Pain Score</measure>
    <time_frame>Baseline, Month 3 (Day 7)</time_frame>
    <description>Patient self-reported pain scores assessed using a VAS ranging from 0 to 10 where 0 indicates &quot;no pain&quot;, 4 through 6 reflect &quot;moderate pain&quot;, and 10 reflects &quot;worst possible pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 6 in the Pain Score</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Patient self-reported pain scores assessed using a VAS ranging from 0 to 10 where 0 indicates &quot;no pain&quot;, 4 through 6 reflect &quot;moderate pain&quot;, and 10 reflects &quot;worst possible pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 12 in the Pain Score</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Patient self-reported pain scores assessed using a VAS ranging from 0 to 10 where 0 indicates &quot;no pain&quot;, 4 through 6 reflect &quot;moderate pain&quot;, and 10 reflects &quot;worst possible pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in American Chronic Pain Association (ACPA) Quality of Life (QOL) score from baseline to Month 1</measure>
    <time_frame>Baseline, Month 1 (day 7)</time_frame>
    <description>The ACPA QOL is a self-administered questionnaire measuring functionality for people with pain which looks at the ability to function, rather than pain alone and is intended to measure activity levels. The ACPA QOL consists of 10 possibilities ranging from 0 to 10 where 0 represents &quot;Non-functioning&quot; and 10 represents &quot;Normal Quality of Life&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ACPA QOL score from baseline to Month 2</measure>
    <time_frame>Baseline, Month 2 (day 7)</time_frame>
    <description>The ACPA QOL is a self-administered questionnaire measuring functionality for people with pain which looks at the ability to function, rather than pain alone and is intended to measure activity levels. The ACPA QOL consists of 10 possibilities ranging from 0 to 10 where 0 represents &quot;Non-functioning&quot; and 10 represents &quot;Normal Quality of Life&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ACPA QOL score at Month 3</measure>
    <time_frame>Baseline, Month 3 (day 7)</time_frame>
    <description>The ACPA QOL is a self-administered questionnaire measuring functionality for people with pain which looks at the ability to function, rather than pain alone and is intended to measure activity levels. The ACPA QOL consists of 10 possibilities ranging from 0 to 10 where 0 represents &quot;Non-functioning&quot; and 10 represents &quot;Normal Quality of Life&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ACPA QOL score at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The ACPA QOL is a self-administered questionnaire measuring functionality for people with pain which looks at the ability to function, rather than pain alone and is intended to measure activity levels. The ACPA QOL consists of 10 possibilities ranging from 0 to 10 where 0 represents &quot;Non-functioning&quot; and 10 represents &quot;Normal Quality of Life&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ACPA QOL score at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>The ACPA QOL is a self-administered questionnaire measuring functionality for people with pain which looks at the ability to function, rather than pain alone and is intended to measure activity levels. The ACPA QOL consists of 10 possibilities ranging from 0 to 10 where 0 represents &quot;Non-functioning&quot; and 10 represents &quot;Normal Quality of Life&quot;.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Headache</condition>
  <condition>Cognitive Disturbance</condition>
  <condition>Skin Hyperpigmentation</condition>
  <condition>Arthralgia</condition>
  <arm_group>
    <arm_group_label>Calcium DTPA followed by Zinc DTPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive IV administration of Ca-DTPA on Day 1 and Zn-DTPA on Day 2 at each of treatment time-points. Three identical treatment time-points are scheduled on Month 1, Month 2 and Month 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium DTPA</intervention_name>
    <description>On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.
The same treatment therapy will consist of 3 time-points, approximately 1 month apart.</description>
    <arm_group_label>Calcium DTPA followed by Zinc DTPA</arm_group_label>
    <other_name>Pentetate calcium trisodium injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc DTPA</intervention_name>
    <description>On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.
The same treatment therapy will consist of 3 time-points, approximately 1 month apart.</description>
    <arm_group_label>Calcium DTPA followed by Zinc DTPA</arm_group_label>
    <other_name>Pentetate zinc trisodium injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Exhibiting 3 or greater of the following symptoms which must be
        present after having been administered a GBCA:

          -  Cognitive disturbance

          -  Extremity pain

          -  Headache

          -  Chest wall pain

          -  Skin induration

          -  Skin hyperpigmentation

          -  Skin pain

          -  Arthralgia

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Less than 18 years old

          -  No evidence of gadolinium (has to have shown previous demonstration of Gd by urine
             analysis or bone biopsy)

          -  Known connective tissue disease such as Systemic Lupus Erythematosus or Scleroderma

          -  Severe hemochromatosis or Wilson's disease

          -  Glomerular Filtration Rate (GFR) â‰¤ 60

          -  Have had an investigational drug within last 30 days

          -  Unable to give written consent

          -  Multiple Sclerosis

          -  Chronic heart failure

          -  Cirrhosis of the liver
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Semelka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>October 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gadolinium</keyword>
  <keyword>deposition</keyword>
  <keyword>GBCA</keyword>
  <keyword>Extremity Pain</keyword>
  <keyword>Skin Pain</keyword>
  <keyword>Chest Wall Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Hyperpigmentation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
